SynthesisFrontiers in oncology2026
Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence.
Yu Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.